 |
| Biodesix CEO David Brunel |
Biodesix reeled in an additional $12 million in Series E financing for its blood-based test for non-small cell lung cancer, bringing the company's proceeds from the sale to $27 million. The Boulder, CO-based molecular diagnostic outfit plans to use the funds to ramp up development for its VeriStrat tool, which helps oncologists decide whether to treat advanced lung cancer patients with Roche's ($RHHBY) Tarceva (erlotinib) or traditional chemotherapy. "Securing this investment enables us to effectively bring innovative diagnostics to market that help inform treatment decisions and improve patient care in a cost effective manner," CEO David Brunel said in a statement. More from FierceMedicalDevices